Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer
about
P1343
Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targetingTwenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic LandscapesHDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells.Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1.EWS-FLI1 employs an E2F switch to drive target gene expression.EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma.Crosstalk analysis of pathways in breast cancer using a network model based on overlapping differentially expressed genes.SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.Uncovering drug-responsive regulatory elements.YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model.Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.MicroRNA-432 functions as a tumor suppressor gene through targeting E2F3 and AXL in lung adenocarcinoma.18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma.RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein.Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination SystemLysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.Molecular pathology and prostate cancer therapeutics: from biology to bedside.Recent advances in the structural molecular biology of Ets transcription factors: interactions, interfaces and inhibition.Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma.Knockdown of EWSR1/FLI1 expression alters the transcriptome of Ewing sarcoma cells in vitro.EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.Next steps in Ewing sarcoma (epi-)genomics.EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma.Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.miR-141 suppresses the growth and metastasis of HCC cells by targeting E2F3.EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.Determination of the physiological and pathological roles of E2F3 in adult tissues.Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription FactorRobust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets.Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.[Chemotherapeutic concepts for bone sarcomas].Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers
P2860
Q26768602-D12C7A71-D605-4651-BD02-101E19DC0D1FQ26782649-AE8E0701-0431-4477-B133-D4AD2E6A4E8BQ26801785-96491301-0898-49C6-866F-FF037D6EC969Q33917640-7ABE43C9-CD3B-4403-B5F6-0E7AF3BB0737Q34464009-DEBBCA4D-77A3-4125-AEB6-BE609FAD150EQ35171620-76FDE641-1BBB-4B6D-B4EB-7073DA6C20F2Q35820934-A875F5E9-5D3B-4815-8209-D5848AE2CD7FQ35870241-452E3A63-0808-42FD-A7E7-6B315256D242Q36069053-0BBD3D08-848F-4EF2-BB31-605CEEA4E5FBQ36473365-1EFAFB49-1F55-48EB-B09F-218CF4356348Q36545848-2B29AE9B-FAE2-44BC-8610-D75661FCD600Q36584775-CBBE0E37-6C35-4072-9738-BD1DE4726632Q37190245-6A5B9238-8470-4CA8-8409-335F8D573972Q37285365-A0ECB808-A7BB-4A0B-850E-F4254CD9436DQ37564718-2E3FD913-9484-4161-A407-0E855CE2949CQ37611723-B70B6D13-DF12-44ED-98A9-A3D00B154AB3Q37636670-3A78F7EE-4787-4C71-B753-4B196CB89D25Q38151036-0ED70FE5-9143-4E52-AB0D-CFF221B4C13BQ38180770-BF535148-00B5-41A9-B5B7-5DCF5321C259Q38243878-0FB3C5B2-6CDE-4BBC-B6FF-1D26BCF3D466Q38373823-02DCB75E-3BC0-4827-AFD6-86C880C599DBQ38438759-99D5BED5-1FC5-48A1-9850-95A4C3FB103FQ38673285-BE0000AD-99E3-4C0F-94D4-8E46301D777DQ38673853-16D02740-F9B3-4142-A61C-ECE1FB645819Q38696838-8E12A0AD-3481-4F58-90DB-5D8597BB4BA0Q38916006-569AE19A-C5A7-45E7-9C05-78B5D7806C25Q38964260-E80D6DCB-D232-40AD-8DF5-17033AF59289Q39634845-01D827CA-EF81-4303-838C-2CAB17B89E9AQ41566089-02A21EA2-E275-4B48-8650-A2DF9F52BB0CQ41739827-A7A391C4-C61A-4ACC-80A7-C5A1CF66605EQ49166444-D6FAA116-147D-42EF-8F3A-90D1152E205BQ50067605-52D6E062-129E-4332-8AB5-1980CEF9337AQ50803781-A38EA1B2-FF2F-4293-A5A7-11E6EBA1EE35Q57174958-A8999C58-E1DF-4162-AA12-13B00BE309C4
P2860
Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer
@en
Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer.
@nl
type
label
Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer
@en
Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer.
@nl
prefLabel
Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer
@en
Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer
@en
P2093
Gunhild Jug
Heinrich Kovar
Marbin Pineda
Maximilian Kauer
Paul S Meltzer
Raphaela Schwentner
Robert L Walker
Sean Davis
Sven Bilke
P2860
P304
P356
10.1101/GR.151340.112
P4510
P577
2013-08-12T00:00:00Z